Sorrento Therapeutics Company Profile (NASDAQ:SRNE)

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $154.38 million
  • Outstanding Shares: 75,309,000
Average Prices:
  • 50 Day Moving Avg: $1.88
  • 200 Day Moving Avg: $3.26
  • 52 Week Range: $1.50 - $8.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.73
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $12.04 million
  • Price / Sales: 12.82
  • Book Value: $1.33 per share
  • Price / Book: 1.54
Profitability:
  • EBIDTA: ($67,940,000.00)
  • Net Margins: -593.94%
  • Return on Equity: -84.07%
  • Return on Assets: -21.75%
Debt:
  • Debt-to-Equity Ratio: 0.42%
  • Current Ratio: 0.59%
  • Quick Ratio: 0.59%
Misc:
  • Average Volume: 1.05 million shs.
  • Beta: 1.55
  • Short Ratio: 2.11
 
Frequently Asked Questions for Sorrento Therapeutics (NASDAQ:SRNE)

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) announced its earnings results on Monday, November, 16th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $1.10 million for the quarter, compared to analysts' expectations of $1.28 million. Sorrento Therapeutics had a negative net margin of 593.94% and a negative return on equity of 84.07%. View Sorrento Therapeutics' Earnings History.

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?

5 brokers have issued 1-year price targets for Sorrento Therapeutics' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Sorrento Therapeutics' share price to reach $16.00 in the next twelve months. View Analyst Ratings for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:

  • William S. Marth, Independent Chairman of the Board
  • Henry H. Ji Ph.D., President, Chief Executive Officer, Director
  • Kevin Herde, Chief Financial Officer, Executive Vice President
  • Mike Royal M.D., Executive Vice President - Clinical and Regulatory Affairs
  • Miranda Jayne Toledano, Executive Vice President - Corporate Development
  • George Uy, Executive Vice President, Chief Commercial Officer
  • David Miao, Chief Technology Officer
  • Jaisim Shah, Director
  • Yue Wu Ph.D., Director
  • David H. Deming, Independent Director

Who owns Sorrento Therapeutics stock?

Sorrento Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Crow Point Partners LLC (0.13%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Crow Point Partners LLC. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $2.05.


MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)
Community Ranking:  4.7 out of 5 (   )
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sorrento Therapeutics (NASDAQ:SRNE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (680.49% upside)

Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/4/2017HC WainwrightSet Price TargetBuy$20.00HighView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy -> Buy$30.00 -> $20.00HighView Rating Details
11/2/2016Roth CapitalSet Price TargetBuy$15.00N/AView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
8/3/2015MLV & Co.Initiated CoverageBuy$34.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)
Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Earnings History by Quarter for Sorrento Therapeutics (NASDAQ SRNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
2017 EPS Consensus Estimate: ($1.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 17.51%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2017Henry JiInsiderBuy29,001$1.81$52,491.81View SEC Filing  
6/15/2017Jaisim ShahDirectorBuy10,002$1.79$17,903.58View SEC Filing  
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.00View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.00View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.00View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.00View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.00View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sorrento Therapeutics (NASDAQ:SRNE)
Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $20.00 Price Target
www.americanbankingnews.com - July 9 at 4:52 PM
americanbankingnews.com logo$4.40 Million in Sales Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter
www.americanbankingnews.com - July 2 at 11:02 AM
streetinsider.com logoSorrento Therapeutics (SRNE) Reports FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
www.streetinsider.com - July 1 at 7:48 AM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 7:48 AM
americanbankingnews.com logo Brokerages Expect Sorrento Therapeutics, Inc. (SRNE) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - June 30 at 11:20 AM
nasdaq.com logoHealth Care Sector Update for 06/29/2017: SRNE,OBSV,BLCM - Nasdaq
www.nasdaq.com - June 30 at 6:56 AM
prnewswire.com logoSorrento Therapeutics Announced FDA Authorization of IND to ... - PR Newswire (press release)
www.prnewswire.com - June 30 at 6:56 AM
finance.yahoo.com logoSorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
finance.yahoo.com - June 30 at 6:56 AM
finance.yahoo.com logoSemnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102
finance.yahoo.com - June 27 at 8:41 AM
americanbankingnews.com logoSorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - June 19 at 12:04 AM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : June 16, 2017
finance.yahoo.com - June 17 at 6:21 AM
americanbankingnews.com logoSorrento Therapeutics, Inc. (SRNE) Short Interest Update
www.americanbankingnews.com - June 15 at 10:46 PM
streetinsider.com logoSorrento Therapeutics (SRNE) Subsidiary Announces Positive Data from Head to Head Adhesion Study with ZTlido
www.streetinsider.com - June 15 at 9:23 PM
americanbankingnews.com logoInsider Buying: Sorrento Therapeutics, Inc. (SRNE) Insider Acquires 29,001 Shares of Stock
www.americanbankingnews.com - June 15 at 8:06 PM
americanbankingnews.com logoSorrento Therapeutics, Inc. (SRNE) Director Buys $17,903.58 in Stock
www.americanbankingnews.com - June 15 at 8:06 PM
prnewswire.com logoSorrento Therapeutics Contributes to the Formation of Celularity, Inc. - PR Newswire (press release)
www.prnewswire.com - June 15 at 1:13 AM
finance.yahoo.com logoSorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™
finance.yahoo.com - June 15 at 1:13 AM
finance.yahoo.com logoSorrento Therapeutics Announces Dismissal Of Lawsuits
finance.yahoo.com - June 15 at 1:13 AM
finance.yahoo.com logoSorrento Therapeutics Contributes to the Formation of Celularity, Inc.
finance.yahoo.com - June 13 at 9:45 AM
prnewswire.com logoTechnical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics - PR Newswire (press release)
www.prnewswire.com - June 9 at 8:49 AM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $4.40 Million
www.americanbankingnews.com - June 7 at 8:46 AM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) Expected to Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - June 5 at 10:08 PM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 10:06 PM
finance.yahoo.com logoSorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 1:35 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Sorrento Therapeutics Inc's Q3 2017 Earnings (SRNE)
www.americanbankingnews.com - May 24 at 8:08 AM
americanbankingnews.com logoHC Wainwright Reiterates "$20.00" Price Target for Sorrento Therapeutics Inc (SRNE)
www.americanbankingnews.com - May 23 at 8:43 PM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) PT Lowered to $20.00
www.americanbankingnews.com - May 22 at 8:16 AM
americanbankingnews.com logoFBR & Co Trims Sorrento Therapeutics Inc (SRNE) Target Price to $9.00
www.americanbankingnews.com - May 22 at 8:16 AM
streetinsider.com logoSorrento Therapeutics (SRNE) Announces Completion of GMP Manufacturing Plant in Suzhou, China - StreetInsider.com
www.streetinsider.com - May 4 at 8:41 PM
finance.yahoo.com logoSorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business
finance.yahoo.com - May 4 at 10:51 AM
americanbankingnews.com logoSorrento Therapeutics (SRNE) Earning Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:24 PM
bizjournals.com logoOpioid-fighting startup lands CEO, COO with deep pharmaceutical expertise
www.bizjournals.com - May 3 at 6:10 PM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 5:50 PM
prnewswire.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release)
www.prnewswire.com - April 30 at 3:32 PM
prnewswire.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release)
www.prnewswire.com - April 30 at 3:32 PM
americanbankingnews.com logoSorrento Therapeutics (SRNE) Receiving Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 29 at 8:28 PM
finance.yahoo.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu ... - Yahoo Finance
finance.yahoo.com - April 29 at 2:15 AM
finance.yahoo.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
finance.yahoo.com - April 28 at 4:13 PM
americanbankingnews.com logoSorrento Therapeutics (SRNE) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 7:40 PM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) Major Shareholder Purchases $1,100,000.00 in Stock
www.americanbankingnews.com - April 21 at 12:27 PM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 8:06 PM
americanbankingnews.com logoInsider Buying: Sorrento Therapeutics Inc (SRNE) CEO Buys 100,000 Shares of Stock
www.americanbankingnews.com - April 19 at 10:45 PM
seekingalpha.com logoSorrento Therapeutics up 9% as CEO adds to stake
seekingalpha.com - April 19 at 7:58 PM
finance.yahoo.com logoSorrento Announces Closing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 7:58 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Very Unlikely to Impact Sorrento Therapeutics (SRNE) Stock Price
www.americanbankingnews.com - April 18 at 3:42 PM
americanbankingnews.com logoInsider Buying: Sorrento Therapeutics Inc (SRNE) Major Shareholder Buys 2,500,000 Shares of Stock
www.americanbankingnews.com - April 18 at 8:23 AM
streetinsider.com logoSorrento Therapeutics (SRNE) Prices 23.63M Common Stock Offering at $2/Share - StreetInsider.com
www.streetinsider.com - April 15 at 6:35 PM
streetinsider.com logoSorrento Therapeutics (SRNE) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - April 14 at 3:43 PM
americanbankingnews.com logoSomewhat Negative Press Coverage Somewhat Likely to Impact Sorrento Therapeutics (SRNE) Stock Price
www.americanbankingnews.com - April 14 at 3:26 PM
finance.yahoo.com logoSorrento Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 13 at 7:48 PM

Social

Chart

Sorrento Therapeutics (SRNE) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff